[Skip to Content]
[Skip to Content Landing]
September 1986

Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

Arch Neurol. 1986;43(9):933-935. doi:10.1001/archneur.1986.00520090061018

• Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.